United Research Institute of SINOVAC serves as the innovation source and drug discovery engine for SINOVAC, committed to "Connecting the power of global science and promoting global health". Focusing on clinical needs in major global disease areas, it integrates cutting-edge basic scientific research and significant achievements, concentrating superior forces to develop first-in-class innovative biologics such as vaccines, antibodies, and fusion proteins, aiming for rapid market entry of high-value products.
Leveraging SINOVAC’s R&D platform, United Research Institute of SINOVAC plans to establish a "high-precision, cutting-edge biopharmaceutical frontier results transformation base" in Changping District, Beijing, adjacent to the Life Science Park. With a total construction area of 120,000 square meters, it will be operational by 2024. The projects and innovative pharmaceutical products from the United Research Institute of SINOVAC and research institutions will be implemented here. Creating a global frontier R&D platform and adopting a "self-use + collaboration" operation model, this base will connect with cutting-edge biopharmaceutical achievements, providing R&D, pilot testing, and industrialization platform support to accelerate transformations.
The Pharmaceutical Development Department upholds SINOVAC’s mission of “providing vaccines to eliminate human diseases” .Through platform-based resource allocation and efficient collaboration mechanisms, it undertakes the development and quality research of various company products. Currently, the team has grown to 400 members, with laboratories and pilot plants covering a total of 55,700 square meters. It has three major process development platforms: the Vaccine Center, the mRNA Center and the Antibody Center. Additionally, it has comprehensive quality assurance, quality analysis and animal safety & efficacy evaluation systems, enabling the high-quality and efficient completion of preclinical research for innovative biological products.
Diversified layouthand, foot and mouth disease
meningitis
pertussis
pneumococcus
rabies
rotavirus
60+ national and local research projects
More than 140 papers in SCI journals
Number of patents 90 (granted)/150 (filed)
Institute of Biophysics, Chinese Academy of Sciences
Institute of Microbiology, Chinese Academy of Sciences
The PLA Academy of Military Science's Military Medical Institute
National Institute for Viral Disease Control and Prevention
Division of Infectious Disease, Chinese Centre for Disease Control and Prevention
Institute of Laboratory Animals Science, CAMS & PUMC
China Institute for food and drug control
Beijing Institute for drug control
National Center for drug safety evaluation and monitoring (Beijing)
National Shanghai Center for New Drug Safety Evaluation Research
National Institutes of Health (NIH)
American Type Culture Collection (ATCC)
National Institute for Biological Standards and Control (NIBSC)
Centers for Disease Control and Prevention (CDC)
INTRAVACC
Tsinghua University
Third Military Medical University
China Agricultural University
Beijing Normal University
University of Cambridge
The University of Sydney
The University of Alabama
The Second Affiliated Hospital, Army Medical University (Xinqiao Hospital)
EN
.png)
.png)
.png)
.png)
(1).png)
(1).png)
(1).png)
